Literature DB >> 26089731

Patient with inoperable pheochromocytoma.

D Brancíková1, Z Mechl1, Z Adam1, E Jandáková2, Z Pavlovský3, V Válek3, Z Andrašina3.   

Abstract

Malignant pheochromocytoma is a tumour with a very low incidence that occurs sporadically or in the presence of multiple endocrine neoplasia. We present the case of a woman with a sporadic occurrence of pheochromocytoma diagnosed in the phase of multiple dissemination in the abdominal cavity and overexpressing adrenaline, noradrenaline, and dopamine. Local transarterial chemoembolization and systemic treatment with lanreotide resulted in a very good response, a decrease in the production of catecholamines for 12 months and a partial decrease for another 8 months, with stabilization of disease determined by imaging. Systemic treatment with tegafur resulted in disease stabilization lasting 50 months, after which the drug was discontinued because of adverse effects. Maintenance therapy with lanreotide continues, and no disease progression has been observed for 4 months. The treatment algorithm for such patients is multidisciplinary and must always take into account the current scope of the disease, intercurrence, and the general condition of the patient.

Entities:  

Keywords:  Pheochromocytoma; chemoembolization; lanreotide

Year:  2015        PMID: 26089731      PMCID: PMC4462542          DOI: 10.3747/co.22.2324

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  19 in total

1.  Successful treatment of malignant pheochromocytoma with combination chemotherapy containing anthracycline.

Authors:  M Nakane; S Takahashi; I Sekine; I Fukui; M Koizumi; K Kage; Y Ito; K Aiba; N Horikoshi; K Hatake; Y Ishikawa; E Ogata
Journal:  Ann Oncol       Date:  2003-09       Impact factor: 32.976

Review 2.  Malignant pheochromocytoma with liver metastasis treated by transcatheter arterial chemo-embolization (TACE).

Authors:  Satoshi Hidaka; Atsushi Hiraoka; Hironori Ochi; Takahide Uehara; Tomoyuki Ninomiya; Yasunao Miyamoto; Aki Hasebe; Tetsuya Tanihira; Atsushi Tanabe; Misa Ichiryu; Hiromasa Nakahara; Nayu Tazuya; Iku Ninomiya; Kojiro Michitaka
Journal:  Intern Med       Date:  2010-04-01       Impact factor: 1.271

3.  Effect of octreotide on catecholamine plasma levels in patients with chromaffin cell tumors.

Authors:  C Invitti; I De Martin; G B Bolla; F Pecori Giraldi; E Maestri; G Leonetti; F Cavagnini
Journal:  Horm Res       Date:  1993

Review 4.  Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma.

Authors:  Camilo Jimenez; Eric Rohren; Mouhammed Amir Habra; Thereasa Rich; Paola Jimenez; Montserrat Ayala-Ramirez; Eric Baudin
Journal:  Curr Oncol Rep       Date:  2013-08       Impact factor: 5.075

5.  Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.

Authors:  Sara Gonias; Robert Goldsby; Katherine K Matthay; Randall Hawkins; David Price; John Huberty; Lloyd Damon; Charles Linker; Aimee Sznewajs; Steve Shiboski; Paul Fitzgerald
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

6.  Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).

Authors:  M R Druce; G A Kaltsas; M Fraenkel; D J Gross; A B Grossman
Journal:  Horm Metab Res       Date:  2009-05-07       Impact factor: 2.936

7.  Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells.

Authors:  Daniela Pasquali; Valentina Rossi; Giovanni Conzo; Giuseppe Pannone; Pantaleo Bufo; Annamaria De Bellis; Andrea Renzullo; Giuseppe Bellastella; Annamaria Colao; Gianfranco Vallone; Antonio Bellastella; Antonio A Sinisi
Journal:  J Mol Endocrinol       Date:  2008-06       Impact factor: 5.098

Review 8.  Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas.

Authors:  Aoife J Lowery; Siun Walsh; Enda W McDermott; Ruth S Prichard
Journal:  Oncologist       Date:  2013-04-10

9.  Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.

Authors:  Anthony M Joshua; Shereen Ezzat; Sylvia L Asa; Andrew Evans; Reuben Broom; Marc Freeman; Jennifer J Knox
Journal:  J Clin Endocrinol Metab       Date:  2008-11-11       Impact factor: 5.958

10.  Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients.

Authors:  Hui Huang; Jame Abraham; Elizabeth Hung; Steven Averbuch; Maria Merino; Seth M Steinberg; Karel Pacak; Tito Fojo
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.